Report Code: A03369 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Osteoarthritis (OA) also known as degenerative joint disease or degenerative arthritis is among the common chronic conditions of the joint. OA can affect any joint in the knees, hips, lower back, and neck. When an individual suffers from OA, the cartilage that provides a smooth, gliding surface for joint motion breaks down, causing pain, swelling, and other issues in the movement of the joints in the body. Osteoarthritis pain drugs are used to relieve the pain that occurs when a person suffers from OA. As per the figures provided by Arthritis Foundation U.S. osteoarthritis (OA) is the most common chronic condition of the joints, affecting approximately 27 million Americans; this high prevalence creates a need for OA pain drugs.
The market is mainly driven by factors such as a strong pipeline portfolio coupled with the increasing prevalence of OA globally. As per World Health Organization, osteoarthritis is already one of the ten most disabling diseases in developed countries. WHO also states that worldwide estimates for OA reports that 9.6% of men and 18.0% of women aged over 60 years have symptomatic osteoarthritis. 80% of those with osteoarthritis will have limitations in movement and 25% cannot perform their major daily activities of life. However, the side effects of the drugs and loss of patent exclusivity of branded therapies may restrict the growth of the market.
The report segments the osteoarthritis pain drugs market on the basis of drug class, route of administration, dosage form, and geography. On the basis of drug class, the market is categorized into NSAIDs, opioids, viscosupplements, corticosteroids, and others. Based on the route of administration, the market is segmented into oral, parenteral, and topical. Based on the dosage form, the market is segmented into solid, liquid, and semi-solid. The geographic breakdown and deep analysis of each of the aforesaid segments has been covered for North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as Abbott Laboratories, Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Eli Lilly and Company, and others have also been provided in this report.
KEY BENEFITS
Osteoarthritis Pain Drugs Market Report Highlights
Aspects | Details |
---|---|
By Drug Class |
|
By Route of Administration |
|
By Dosage Form |
|
By Region |
|
Key Market Players | Medivir,, Pfizer Inc.,, Merck Sharp & Dohme Corp.,, Eli Lilly and Company,, Ferring B.V.,, Bioventus, Inc.,, Sanofi, S.p.A, Horizon Pharma plc.,, Abbott,, ABIOGEN PHARMA |
Loading Table Of Content...
Start reading.
This Report and over 71,323+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time for readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers